Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-921: Pembrolizumab plus Docetaxel in mCRPC
NCT03834506Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2019
- Primary completion
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Pembrolizumab + Docetaxel with Placebo + Docetaxel (2 arms). Primary endpoints: Overall Survival up to 36.5 months and Radiographic Progression-free Survival up to 28 months. Started May 2019; status: completed.
02
Drugs
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03834506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03834506.